In this article, we discuss the 5 best dividend stocks to buy according to Alan Frazier. If you want to read our detailed analysis of Frazier’s history and hedge fund performance, go directly to the 10 Best Biotech Stocks to Buy According to Alan Frazier.
5. Epizyme, Inc. (NASDAQ: EPZM)
Frazier’s Stake Value: $6,440,000
Percentage of Alan Frazier’s 13F Portfolio: 0.51%
Number of Hedge Fund Holders: 16
Epizyme, Inc. (NASDAQ: EPZM) is an American biopharmaceutical company, which discovers, develops, and sells medicines for patients with cancer and other diseases. The company was incorporated in 2007 and is ranked fifth on the list of 10 best biotech stocks to buy according to Alan Frazier. Epizyme currently has a market capitalization of $872.91.
On May 7, Andrew Berens, an analyst at SVB Leerink, initiated coverage on Epizyme (NASDAQ: EPZM), rating the stock as “Outperform,” with a price target of $16. On May 6, the company posted revenue for the first quarter of 2021. It declared revenue of $7.63 million, up 465.2% YoY, beating the estimates by $0.76 million.
The hedge fund chaired by Frazier holds 739,369 shares in the company worth $6.44 million. Frazier Healthcare Partners increased its stake in Epizyme, Inc. (NASDAQ: EPZM) by 2% in the past few months. Redmile Group owns 8.82 million shares of Epizyme (NASDAQ: EPZM), worth $76.86 million, topping the list of over 850 hedge funds tracked by Insider Monkey.
4. Immunovant, Inc. (NASDAQ: IMVT)
Frazier’s Stake Value: $8,148,000
Percentage of Alan Frazier’s 13F Portfolio: 0.65%
Number of Hedge Fund Holders: 26
Immunovant, Inc. (NASDAQ: IMVT) is a biopharma company that develops monoclonal antibodies to treat chronic diseases. The company was founded in 2018 and stands fourth on the list of 10 best biotech stocks to buy according to Alan Frazier. The company has a $1.06 billion market capitalization.
On June 1, Immunovant, Inc. (NASDAQ: IMVT) posted earnings results for the first three months of 2021. The earnings per share was -$0.29, beating market predictions by $0.04. The company also announced that it is planning to restart clinical development of IMVT-1401 in Myasthenia Gravis and a phase two study in Warm Autoimmune Hemolytic Anemia in late 2021 or early 2022.
The stock is a new arrival on Alan Frazier’s portfolio, as his hedge fund bought about 508,000 shares of Immunovant, Inc. (NASDAQ: IMVT), worth $8.15 million. Out of the hedge funds being tracked by Insider Monkey, Biotechnology Value Fund / BVF Inc is the biggest stakeholder of the company with 1.14 million shares, worth $18.35 million.
3. ESSA Pharma Inc. (NASDAQ: EPIX)
Frazier’s Stake Value: $9,198,000
Percentage of Alan Frazier’s 13F Portfolio: 0.73%
Number of Hedge Fund Holders: 28
ESSA Pharma Inc. (NASDAQ: EPIX) is a pharmaceutical company that develops therapies for the treatment of prostate cancer. It was founded in 2009 and is placed third on the list of 10 best biotech stocks to buy according to Alan Frazier. ESSA stock has returned 371.82% to investors over the course of the past 12 months.
On February 17, ESSA Pharma Inc. (NASDAQ: EPIX) announced that it launched an underwritten offering in which it offered ~4.8 million common stock shares. The net proceeds from the public offering will be used for pre-clinical and clinical activities, producing and controlling, financial assets, and general corporate purposes. On March 4, Tyler Van Buren, an analyst at Piper Sandler, initiated coverage on ESSA Pharma, rating the stock as “Overweight,” with a price target of $50.
Alan Frazier’s hedge fund owns 316,616 shares of ESSA Pharma Inc. (NASDAQ: EPIX), worth $9.20 million. The company is getting the attention of the smart money, as 28 elite hedge funds held stakes in the company in the first quarter of 2021, up from 18 funds a quarter earlier.
2. Krystal Biotech, Inc. (NASDAQ: KRYS)
Frazier’s Stake Value: $68,951,000
Percentage of Alan Frazier’s 13F Portfolio: 5.53%
Number of Hedge Fund Holders: 8
Krystal Biotech, Inc. (NASDAQ: KRYS) is an American biotech company engaged in the field of redosable gene therapy to treat serious rare diseases. The company was incorporated in 2015 and is ranked second on the list of 10 best biotech stocks to buy according to Alan Frazier. Krystal currently has a $1.53 billion market capitalization. It delivered a 48.72% return in the past 12 months.
On March 30, Krystal Biotech, Inc. (NASDAQ: KRYS) declared that it completed enlistment in the GEM-3 study of B-VEC for dystrophic epidermolysis bullosa. The trial registered 31 patients ranging in ages from 1 to 44 years old. On February 9, Jones Trading initiated coverage on Krystal Biotech with a “Buy” rating and a price target of $97.
Frazier Healthcare Partners owns 895,000 shares of Krystal Biotech, worth $68.95 million, making it the second-largest company stakeholder. Redmile Group is a leading shareholder in Krystal Biotech, Inc. (NASDAQ: KRYS), with 2.06 million shares worth $158.71 million, representing 2.23% of its portfolio.
1. REGENXBIO Inc. (NASDAQ: RGNX)
Frazier’s Stake Value: $12,005,000
Percentage of Alan Frazier’s 13F Portfolio: 0.96%
Number of Hedge Fund Holders: 22
REGENXBIO Inc. (NASDAQ: RGNX) is a biotechnology company seeking to improve lives through the medicinal potential of gene therapy. It was founded in 2008 and is placed first on the list of 10 best biotech stocks to buy according to Alan Frazier.
On May 14, Regenxbio (NASDAQ: RGNX) announced a safety update and additional positive information from the Phase I/II trial of RGX-121 for the medication of patients up to 5 years old diagnosed with Hunter Syndrome. RGX-121 is declared to be well-tolerated with no serious side effects. On May 5, the company posted earnings for the first quarter of 2021. It reported earnings per share of -$1.20, beating market predictions by $0.02.
Frazier Healthcare Partners holds 351,954 shares in the company worth $12.01 million, representing 0.96% of their portfolio. The fund has increased stakes in the firm by 3% in the past few months. Redmile Group is a leading shareholder in Regenxbio (NASDAQ: RGNX), with 2.34 million shares worth $79.83 million, representing 1.12% of its portfolio.
You can also take a peek at 10 Best Biotech Stocks To Buy For 2021 and 10 Best Biotech Stocks Under $6 in 2021.
